| abstract |
This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ) and methods of use thereof. In particular, in vitro methods of predicting a human subject's likely response to treatment with olanzapine, risperidone, perphenazine or ziprasidone, or of selecting a treatment for schizophrenia comprising administration of olanzapine, risperidone, perphenazine or ziprasidone, comprising detecting a haplotype comprising one or more polymorphic markers in UNC5C or markers in linkage desiquilbrium (LD) therewith, are provided. |